Female long-term survivors after allogeneic hematopoietic stem cell transplantation: Evaluation and management

Seminars in Hematology

Volumn 49, Issue 1, 2012, Pages 83-93

  Shanis, Dana ^a   Merideth, Melissa ^b,c   Pulanic, Tajana Klepac ^d   Savani, Bipin N ^e   Battiwalla, Minoo ^f   Stratton, Pamela ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d Department of Gynecology   (Croatia)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; ESTROGEN; IMMUNOSTIMULATING AGENT; TACROLIMUS; WART VIRUS VACCINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BEDTIME DOSAGE; CANCER RISK; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL EVALUATION; CLINICAL FEATURE; COLPOSCOPY; CONDYLOMA ACUMINATUM; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG USE; FEMALE INFERTILITY; HORMONE SUBSTITUTION; HUMAN; LONG TERM SURVIVAL; LOW DRUG DOSE; NONHUMAN; OVARY INSUFFICIENCY; PAPILLOMAVIRUS INFECTION; PATHOGENESIS; PELVIC EXAMINATION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SECOND CANCER; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; TREATMENT INDICATION; UTERINE CERVIX CYTOLOGY; VACCINATION; VAGINAL BURNING SENSATION; VULVOVAGINA CHRONIC GRAFT VERSUS HOST REACTION; VULVOVAGINAL DISEASE;

FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFERTILITY, FEMALE; OSTEOPOROSIS; PAPILLOMAVIRUS INFECTIONS; SURVIVORS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855368450     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2011.10.002     Document Type: Article

References (82)

1. Spinelli S., Chiodi S., Costantini S., et al. Female genital tract graft-versus-host disease following allogeneic bone marrow transplantation. Haematologica 2003, 88:1163-1168.
2. Zantomio D., Grigg A.P., Macgregor L., et al. Female genital tract graft-versus-host disease: incidence, risk factors and recommendations for management. Bone Marrow Transplant 2006, 38:567-572.
3. Stratton P., Turner M.L., Childs R., et al. Vulvovaginal chronic graft-versus-host disease with allogeneic hematopoietic stem cell transplantation. Obstet Gynecol 2007, 110:1041-1049.
4. Riera C., Deroover Y., Marechal M. Severe vaginal chronic graft-versus-host disease (GVHD): two cases with late onset and literature review. Eur J Gynaecol Oncol 2010, 31:703-704.
5. Klepac Pulanic T., Turner M., Gemmill J.A., et al. Female genital chronic graft versus host disease 2010.
6. Flowers M.E., Parker P.M., Johnston L.J., et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002, 100:415-419.
7. Norian J.M., Stratton P. Labial fusion: a rare complication of chronic graft versus host disease. Obstet Gynecol 2008, 112:437-439.
8. Corson S.L., Sullivan K., Batzer F., et al. Gynecologic manifestations of chronic graft-versus-host disease. Obstet Gynecol 1982, 60:488-492.
9. Turner M.L., Stratton P. Gynecological disease. Chronic graft versus host disease interdisciplinary management 2009, 207-215. Cambridge University Press, Oxford, England. G.B. Vogelsang, S.Z. Pavletic (Eds.).
10. Spiryda L.B., Laufer M.R., Soiffer R.J., Antin J.A. Graft-versus-host disease of the vulva and/or vagina: diagnosis and treatment. Biol Blood Marrow Transplant 2003, 9:760-765.
11. Hayes E.C., Rock J.A. Treatment of vaginal agglutination associated with chronic graft-versus-host disease. Fertil Steril 2002, 78:1125-1126.
12. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
13. Cooper S.M., Wojnarowska F. Influence of treatment of erosive lichen planus of the vulva on its prognosis. Arch Dermatol 2006, 142:289-294.
14. Anderson M., Kutzner S., Kaufman R.H. Treatment of vulvovaginal lichen planus with vaginal hydrocortisone suppositories. Obstet Gynecol 2002, 100:359-362.
15. Bachmann G.A., Rosen R., Pinn V.W., et al. Vulvodynia: a state-of-the-art consensus on definitions, diagnosis and management. J Reprod Med 2006, 51:447-456.
16. Milroy C.L., Jones K.P. Gynecologic care in hematopoietic stem cell transplant patients: a review. Obstet Gynecol Surv 2010, 65:668-679.
17. Couriel D., Carpenter P.A., Cutler C., et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2006, 12:375-396.
18. Kolb H.J., Socie G., Duell T., et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med 1999, 131:738-744.
19. Rizzo J.D., Curtis R.E., Socie G., et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009, 113:1175-1183.
20. Bhatia S., Francisco L., Carter A., et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007, 110:3784-3792.
21. Bhatia S., Louie A.D., Bhatia R., et al. Solid cancers after bone marrow transplantation. J Clin Oncol 2001, 19:464-471.
22. Savani B.N., Stratton P., Shenoy A., et al. Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation-implications for screening and HPV vaccination. Biol Blood Marrow Transplant 2008, 14:1072-1075.
23. Pinto L.A., Edwards J., Castle P.E., et al. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis 2003, 188:327-338.
24. Zhang L.F., Zhou J., Chen S., et al. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine 2000, 18:1051-1058.
25. Onozawa M., Hashino S., Darmanin S., et al. HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection. Biol Blood Marrow Transplant 2008, 14:1226-1230.
26. Lewensohn-Fuchs I., Ljungman P., Kjerrstrom A., Ringden O., Dalianis T. Loss of seroreactivity against human papillomavirus (HPV) in bone marrow transplant recipients. Bone Marrow Transplant 1996, 18:333-337.
27. Curtis R.E., Metayer C., Rizzo J.D., et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood 2005, 105:3802-3811.
28. Levi A.W., Harigopal M., Hui P., Schofield K., Chhieng D.C. Use of high-risk human papillomavirus testing in patients with low-grade squamous intraepithelial lesions. Cancer Cytopathol 2011, 119:228-234.
29. ACOG Practice Bulletin no. 109: Cervical cytology screening. Obstet Gynecol 2009, 114:1409-1420.
30. Garland S.M., Hernandez-Avila M., Wheeler C.M., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356:1928-1943.
31. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356:1915-1927.
32. Wilck M.B., Baden L.R. Vaccination after stem cell transplant: a review of recent developments and implications for current practice. Curr Opin Infect Dis 2008, 21:399-408.
33. Bosch F.X., de Sanjosé S. Chapter 1: Human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 2003, (31):3-13.
34. Brown D.R., Kjaer S.K., Sigurdsson K., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009, 199:926-935.
35. Savani B.N., Griffith M.L., Jagasia S., Lee S.J. How I treat late effects in adults after allogeneic stem cell transplantation. Blood 2011, 117:3002-3009.
36. Sanders J.E., Buckner C.D., Amos D., et al. Ovarian function following marrow transplantation for aplastic anemia or leukemia. J Clin Oncol 1988, 6:813-818.
37. Schimmer A.D., Quatermain M., Imrie K., et al. Ovarian function after autologous bone marrow transplantation. J Clin Oncol 1998, 16:2359-2363.
38. Warne G.L., Fairley K.F., Hobbs J.B., Martin F.I.R. Cyclophosphamide-induced ovarian failure. N Engl J Med 1973, 289:1159-1162.
39. Jadoul P., Anckaert E., Dewandeleer A., et al. Clinical and biologic evaluation of ovarian function in women treated by bone marrow transplantation for various indications during childhood or adolescence. Fertil Steril 2011, 96:126-133.
40. Salooja N., Szydlo R.M., Socie G., et al. Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet 2001, 358:271-276.
41. Chatterjee R., Mills W., Katz M., McGarrigle H.H., Goldstone A.H. Prospective study of pituitary-gonadal function to evaluate short-term effects of ablative chemotherapy or total body irradiation with autologous or allogenic marrow transplantation in post-menarcheal female patients. Bone Marrow Transplant 1994, 13:511-517.
42. Teinturier C., Hartmann O., Valteau-Couanet D., Benhamou E., Bougneres P.F. Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure. Bone Marrow Transplant 1998, 22:989-994.
43. Salooja N., Chatterjee R., McMillan A.K., et al. Successful pregnancies in women following single autotransplant for acute myeloid leukemia with a chemotherapy ablation protocol. Bone Marrow Transplant 1994, 13:431-435.
44. Critchley H.O., Wallace W.H. Impact of cancer treatment on uterine function. J Natl Cancer Inst Monogr 2005, 34:64-68.
45. Thibaud E., Ramirez M., Brauner R., et al. Preservation of ovarian function by ovarian transposition performed before pelvic irradiation during childhood. J Pediatr 1992, 121:880-884.
46. Sarafoglou K., Boulad F., Gillio A., Sklar C. Gonadal function after bone marrow transplantation for acute leukemia during childhood. J Pediatr 1997, 130:210-216.
47. Jackson G.H., Wood A., Taylor P.R., et al. Early high dose chemotherapy intensification with autologous bone marrow transplantation in lymphoma associated with retention of fertility and normal pregnancies in females. Scotland and Newcastle Lymphoma Group, UK. Leuk Lymphoma 1997, 28:127-132.
48. Hammer R.A., Urnes P.D., Lurain J.R. Unanticipated pregnancy with intrauterine growth retardation after radiation-induced ovarian failure. A case report. J Reprod Med 1996, 41:372-374.
49. Norwitz E.R., Stern H.M., Grier H., Lee-Parritz A. Placenta percreta and uterine rupture associated with prior whole body radiation therapy. Obstet Gynecol 2001, 98:929-931.
50. Carter A., Robison L.L., Francisco L., et al. Prevalence of conception and pregnancy outcomes after hematopoietic cell transplantation: report from the Bone Marrow Transplant Survivor Study. Bone Marrow Transplant 2006, 37:1023-1029.
51. Liu J., Malhotra R., Voltarelli J., et al. Ovarian recovery after stem cell transplantation. Bone Marrow Transplant 2008, 41:275-278.
52. Somers E.C., Marder W., Christman G.M., Ognenovski V., McCune W.J. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 2005, 52:2761-2767.
53. Del Mastro L., Boni L., Michelotti A., et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 2011, 306:269-276.
54. Lee H.J., Selesniemi K., Niikura Y., et al. Bone marrow transplantation generates immature oocytes and rescues long-term fertility in a preclinical mouse model of chemotherapy-induced premature ovarian failure. J Clin Oncol 2007, 25:3198-3204.
55. Tauchmanovà L., Selleri C., De Rosa G., et al. Endocrine disorders during the first year after autologous stem-cell transplant. Am J Med 2005, 118:664-670.
56. Fish J.D. Part 1: Hormone replacement for survivors of childhood cancer with ovarian failure-when is it worth the risk?. J Pediatr Adolesc Gynecol 2011, 24:98-101.
57. Sklar C.A., Mertens A.C., Mitby P., et al. Premature menopause in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2006, 98:890-896.
58. Rutter M.M., Rose S.R. Long-term endocrine sequelae of childhood cancer. Curr Opin Pediatr 2007, 19:480-487.
59. Chiodi S., Spinelli S., Ravera G., et al. Quality of life in 244 recipients of allogeneic bone marrow transplantation. Br J Haematol 2000, 110:614-619.
60. Claessens J.J., Beerendonk C.C., Schattenberg A.V. Quality of life, reproduction and sexuality after stem cell transplantation with partially T-cell-depleted grafts and after conditioning with a regimen including total body irradiation. Bone Marrow Transplant 2006, 37:831-836.
61. Syrjala K.L., Kurland B.F., Abrams J.R., Sanders J.E., Heiman J.R. Sexual function changes during the 5 years after high-dose treatment and hematopoietic cell transplantation for malignancy, with case-matched controls at 5 years. Blood 2008, 111:989-996.
62. Schover L.R. Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. J Clin Oncol 2008, 26:753-758.
63. Sklar C. Maintenance of ovarian function and risk of premature menopause related to cancer treatment. JNCI Monogr 2005, 2005:25-27.
64. Rosendahl M., Andersen C.Y., la Cour Freiesleben N., et al. Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age. Fertil Steril 2010, 94:156-166.
65. Epstein R.J. Drug-induced DNA damage and tumor chemosensitivity. J Clin Oncol 1990, 8:2062-2084.
66. Somali M., Mpatakoias V., Avramides A., et al. Function of the hypothalamic-pituitary-gonadal axis in long-term survivors of hematopoietic stem cell transplantation for hematological diseases. Gynecol Endocrinol 2005, 21:18-26.
67. Cust M.P., Whitehead M.I., Powles R., Hunter M., Milliken S. Consequences and treatment of ovarian failure after total body irradiation for leukaemia. Br Med J 1989, 299:1494-1497.
68. Hagglund H., Remberger M., Klaesson S., et al. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood 1998, 92:4568-4572.
69. Jeruss J.S., Woodruff T.K. Preservation of fertility in patients with cancer. N Engl J Med 2009, 360:902-911.
70. Balleari E., Garre S., Van Lint M.T., et al. Hormone replacement therapy and chronic graft-versus-host disease activity in women treated with bone marrow transplantation for hematologic malignancies. Ann N Y Acad Sci 2002, 966:187-192.
71. Tauchmanova L., Selleri C., De Rosa G., et al. Estrogen-progestin therapy in women after stem cell transplant: our experience and literature review. Menopause 2007, 14:320-330.
72. Heinonen H., Volin L., Uutela A., et al. Gender-associated differences in the quality of life after allogeneic BMT. Bone Marrow Transplant 2001, 28:503-509.
73. Watson M., Wheatley K., Harrison G.A., et al. Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: analysis of the MRC AML 10 trial. Cancer 1999, 86:1231-1239.
74. Cohen A., Bekassy A.N., Gaiero A., et al. Endocrinological late complications after hematopoietic SCT in children. Bone Marrow Transplant 2008, 41:S43-S48.
75. Stearns V. Serotonergic agents as an alternative to hormonal therapy for the treatment of menopausal vasomotor symptoms. Treat Endocrinol 2006, 5:83-87.
76. Innes K.E., Selfe T.K., Vishnu A. Mind-body therapies for menopausal symptoms: a systematic review. Maturitas 2010, 66:135-149.
77. Kim D.I., Jeong J.C., Kim K.H., et al. Acupuncture for hot flushes in perimenopausal and postmenopausal women: a randomised, sham-controlled trial. Acupunct Med 8 Jun 2011, Epub ahead of print.
78. Warnecke E. What works?. Evidence for lifestyle and nonprescription therapies in menopause. Aust Fam Physician 2011, 40:286-289.
79. Hickey M., Saunders C., Partridge A., et al. Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann Oncol 2008, 19:1669-1680.
80. Spinelli S., Chiodi S., Bacigalupo A., et al. Ovarian recovery after total body irradiation and allogeneic bone marrow transplantation: long-term follow up of 79 females. Bone Marrow Transplant 1994, 14:373-380.
81. Wolff E.F., Kaushal S., Childs R.W., Stratton P. Fertility sparing non-myeloablative allogeneic hematopoietic stem cell transplantation: case series of 11 subsequent pregnancy outcomes. Reprod Sci 2010, 17(suppl):346a.
82. Au W.Y., Leung W.C. Challenges and pitfalls in prenatal screening in pregnancies involving allogeneic stem cell transplantation recipients. Bone Marrow Transplant 2007, 39:379-382.